PROGRAMME SUMMARY
The European Partnership for Personalised Medicine brings together ministries, funding organisations and research institutes from 24 countries and 10 European regions. EP PerMed builds on the results and experience of several international initiatives and projects in the field of personalised medicine, as well as more than 15 years of successful collaboration among many of the partners involved. Over the next ten years (2023-2033), most of EP PerMed’s budget will be available for funding of research projects and the implementation of personalised medicine approaches.
The 1st EP PerMed call will aim to fund research that fosters the identification or validation of targets for personalised medicine approaches. Applicants must combine the research on new and advanced targets with companion biomarker research (companion diagnostics). The final call text will be published early 2024 and will be based on the Strategic Research and Innovation Agenda for Personalised Medicine (SRIA PerMed).
As outlined in the SRIA, additional EP PerMed activities will focus on actions to support and accelerate innovations in personalised medicine and its uptake into healthcare systems. These activities include, for example, partnering events between the research communities and the private sector, calls for personalised medicine pilots, particularly in a regional context, and surveys to identify and contact key players in the healthcare systems and medical societies.
INFORMATION DAY
The JTC2024 Information day will take place on 15 January, 14:00-15:40 (CET). The registration and agenda are now available.
AIMS OF THE CALL
The JTC2024 will aim to fund research that fosters the identification or validation of targets for personalised medicine approaches. Applicants submitting a proposal to this call must combine the research on new and advanced targets with companion biomarker research (companion diagnostics). Consortia are required to be transnational, interdisciplinary and trans-sectoral as well as to clearly outline the personalised medicine perspective in the research proposed.
The overall objectives of the JTC2024 are to
- Support research projects aiming at identifying or validating targets for personalised medicine approaches in combination with development of companion biomarkers or other markers to allow for monitoring of treatment outcomes and patient stratification;
- Encourage and enable interdisciplinary collaborations by combining pre-clinical and clinical research in translational projects, and multi-actor research by engaging a range of other relevant disciplines such as bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to empower the implementation of PM; and
- Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
Research projects in all disease areas are encouraged.
FUNDING SPECIFICS
- The FNR supports this Call with 300,000 EUR.
- Overall budget for this Call is approx. 45 MEUR
APPLICATION INFORMATION
In addition to submitting at ERA PerMed, Luxembourg applicants must also submit the proposal – along with the FNR INTER documents – to the FNR via the FNR Grant Management System no later than 7 working days after the EP PerMed deadline.